220 related articles for article (PubMed ID: 23921486)
1. Mitochondrial delivery of doxorubicin by triphenylphosphonium-functionalized hyperbranched nanocarriers results in rapid and severe cytotoxicity.
Theodossiou TA; Sideratou Z; Katsarou ME; Tsiourvas D
Pharm Res; 2013 Nov; 30(11):2832-42. PubMed ID: 23921486
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
[TBL] [Abstract][Full Text] [Related]
3. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells.
Han M; Vakili MR; Soleymani Abyaneh H; Molavi O; Lai R; Lavasanifar A
Mol Pharm; 2014 Aug; 11(8):2640-9. PubMed ID: 24811541
[TBL] [Abstract][Full Text] [Related]
5. Rational Construction of a Mitochondrial Targeting, Fluorescent Self-Reporting Drug-Delivery Platform for Combined Enhancement of Endogenous ROS Responsiveness.
Li J; Wei YJ; Yang XL; Wu WX; Zhang MQ; Li MY; Hu ZE; Liu YH; Wang N; Yu XQ
ACS Appl Mater Interfaces; 2020 Jul; 12(29):32432-32445. PubMed ID: 32573194
[TBL] [Abstract][Full Text] [Related]
6. Triphenylphosphonium-conjugated glycol chitosan microspheres for mitochondria-targeted drug delivery.
Lee YH; Park HI; Chang WS; Choi JS
Int J Biol Macromol; 2021 Jan; 167():35-45. PubMed ID: 33227331
[TBL] [Abstract][Full Text] [Related]
7. Induction of Mitochondrial Cell Death and Reversal of Anticancer Drug Resistance via Nanocarriers Composed of a Triphenylphosphonium Derivative of Tocopheryl Polyethylene Glycol Succinate.
Singh Y; Viswanadham KKDR; Pawar VK; Meher J; Jajoriya AK; Omer A; Jaiswal S; Dewangan J; Bora HK; Singh P; Rath SK; Lal J; Mishra DP; Chourasia MK
Mol Pharm; 2019 Sep; 16(9):3744-3759. PubMed ID: 31441308
[TBL] [Abstract][Full Text] [Related]
8. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy.
Yu H; Li JM; Deng K; Zhou W; Wang CX; Wang Q; Li KH; Zhao HY; Huang SW
Theranostics; 2019; 9(23):7033-7050. PubMed ID: 31660085
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin derivative loaded acetal-PEG-PCCL micelles for overcoming multidrug resistance in MCF-7/ADR cells.
Zhong XC; Xu WH; Wang ZT; Guo WW; Chen JJ; Guo NN; Wang TT; Lin MT; Zhang ZT; Lu YY; Yang QY; Han M; Xu DH; Gao JQ
Drug Dev Ind Pharm; 2019 Sep; 45(9):1556-1564. PubMed ID: 31271317
[No Abstract] [Full Text] [Related]
10. DNA decorated Cu
Liang S; Xie Z; Wei Y; Cheng Z; Han Y; Lin J
Dalton Trans; 2018 Jun; 47(24):7916-7924. PubMed ID: 29790525
[TBL] [Abstract][Full Text] [Related]
11. Mitochondria-Targeting Polydopamine Nanoparticles To Deliver Doxorubicin for Overcoming Drug Resistance.
Li WQ; Wang Z; Hao S; He H; Wan Y; Zhu C; Sun LP; Cheng G; Zheng SY
ACS Appl Mater Interfaces; 2017 May; 9(20):16793-16802. PubMed ID: 28481505
[TBL] [Abstract][Full Text] [Related]
12. Bioreducible Poly(ethylene glycol)-Triphenylphosphonium Conjugate as a Bioactivable Mitochondria-Targeting Nanocarrier.
Khatun Z; Choi YS; Kim YG; Yoon K; Nurunnabi M; Li L; Lee E; Kang HC; Huh KM
Biomacromolecules; 2017 Apr; 18(4):1074-1085. PubMed ID: 28257184
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
14. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.
Pearce AK; Simpson JD; Fletcher NL; Houston ZH; Fuchs AV; Russell PJ; Whittaker AK; Thurecht KJ
Biomaterials; 2017 Oct; 141():330-339. PubMed ID: 28711780
[TBL] [Abstract][Full Text] [Related]
15. Mitochondria and Nucleus Dual Delivery System To Overcome DOX Resistance.
Cui H; Huan ML; Ye WL; Liu DZ; Teng ZH; Mei QB; Zhou SY
Mol Pharm; 2017 Mar; 14(3):746-756. PubMed ID: 28146635
[TBL] [Abstract][Full Text] [Related]
16. pH Responsive Doxorubicin Delivery by Fluorous Polymers for Cancer Treatment.
Wallat JD; Harrison JK; Pokorski JK
Mol Pharm; 2018 Aug; 15(8):2954-2962. PubMed ID: 29381366
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria-targeted zirconium metal-organic frameworks for enhancing the efficacy of microwave thermal therapy against tumors.
Zhou H; Fu C; Chen X; Tan L; Yu J; Wu Q; Su L; Huang Z; Cao F; Ren X; Ren J; Liang P; Meng X
Biomater Sci; 2018 May; 6(6):1535-1545. PubMed ID: 29670952
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.
Yamada Y; Munechika R; Kawamura E; Sakurai Y; Sato Y; Harashima H
J Pharm Sci; 2017 Sep; 106(9):2428-2437. PubMed ID: 28478130
[TBL] [Abstract][Full Text] [Related]
19. P-Sulfocalix[6]arene as Nanocarrier for Controlled Delivery of Doxorubicin.
Ostos FJ; Lebrón JA; Moyá ML; López-López M; Sánchez A; Clavero A; García-Calderón CB; Rosado IV; López-Cornejo P
Chem Asian J; 2017 Mar; 12(6):679-689. PubMed ID: 28112869
[TBL] [Abstract][Full Text] [Related]
20. A pH-responsive glycolipid-like nanocarrier for optimising the time-dependent distribution of free chemical drugs in focal cells.
Cheng B; Lu B; Liu X; Meng T; Tan Y; Zhu Y; Liu N; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Apr; 522(1-2):210-221. PubMed ID: 28259679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
